MedTrace Logo

Angiogenesis and Fibrosis in Myocardial Infarction

NCT01813045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2016-08-30

No results posted yet for this study

Summary

Angiogenesis and fibrosis lie at the heart of a number of fundamental processes responsible for cardiovascular disease. In this proposal, the investigators intend to build upon a highly successful programme of studies exploring the cardiovascular applications of positron emission tomography. Specifically, the investigators will explore the potential role of a novel radiotracer, 18F-fluciclatide, which is a highly selective ligand for the αvβ3 and αvβ5 integrin receptors that are up regulated during angiogenesis, and tissue fibrosis and remodelling. This tracer has been successfully used to assess angiogenesis in metastatic tumours and its uptake is suppressed by anti-angiogenic therapies. The investigators here propose to describe the pattern of uptake of 18F-fluciclatide in cardiovascular diseases, specifically acute myocardial infarction and aortic atherosclerosis. The investigators will correlate 18F-fluciclatide uptake with in vivo measures of angiogenesis and fibrosis. If successful, this novel radiotracer could provide an extremely important non-invasive method of assessing in vivo angiogenesis, plaque vulnerability, and tissue remodelling as well as potential applications in developing stem cell therapies.

Conditions

Interventions

PROCEDURE

Cardiac MRI scan

Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.

RADIATION

CT-PET scan

Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.

RADIATION

CT-coronary angiogram

CT-coronary angiogram following CT-PET scan. Standard protocol.

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Principal Investigators

  • William SA Jenkins, MBChB · University of Edinburgh / NHS Lothian

  • David E Newby, MBChB PhD · University of Edinburgh / NHS Lothian

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01813045 on ClinicalTrials.gov